|Vietnam||Tiếng Việt English|
|Phone||+65 6836 3665|
|Fax||+65 6235 2744|
MBBS (London), MRCP (United Kingdom), FAMS (Medical Oncology)
|Languages Spoken||Cantonese, English, Mandarin|
Mount Elizabeth Medical Centre
3 Mount Elizabeth #10-11/12
Mount Elizabeth Novena Specialist Centre
38 Irrawaddy Road #05-43,05-50 to 55
Tel: +65 6684 5522
Dr Zee Ying Kiat is a Senior Consultant, Medical Oncologist at Parkway Cancer Centre. He is well versed in general medical oncology and has a special interest in gastro-oesophageal, hepatobiliary, pancreatic and colorectal cancers.
Dr Zee Ying Kiat received his medical degree with dual distinction from University College London. He was also a recipient of the Drummond Prize in Physiology. After being accepted as a Member of the Royal College of Physicians (United Kingdom), Dr Zee Ying Kiat worked at the Royal Marsden Hospital in London before completing specialist training in Medical Oncology at the National University Hospital, Singapore. He subsequently underwent fellowship training at The Christie Hospital and Paterson Institute for Cancer Research in Manchester, where his focus was on anti-cancer drug development.
Before moving to his current practice, he was a Consultant Medical Oncologist at the National University Cancer Institute, Singapore (NCIS).
Dr Zee Ying Kiat is a member of the American Society of Clinical Oncology and founding member of the Hepatopancreatobiliary Association of Singapore. He is the board member of the Mount Elizabeth Hospital Medical Advisory Board, the National Healthcare Group Domain Specific Review Board and the Chapter of Medical Oncologists, College of Physicians, Singapore.
His commitment to research and patient care has been recognized through the receipt of various awards, including the National Medical Research Council Clinician Investigator Support Grant, NCIS Investigator Protected Time Grant and the Excellent Service Award from SPRING Singapore.
At NCIS, Dr Zee Ying Kiat conducted clinical and translational research as principal or co-investigator in local and international trials involving novel targeted therapies for colorectal, gastric, liver and pancreatic cancers. He has published his work as first author in high impact factor journals that include the British Journal of Cancer, Journal of Clinical Oncology, Lancet Oncology and Nature Reviews.